Conditions: Acute Coronary Syndrome
Keywords: Acute Coronary Syndrome ACS Percutaneous Coronary Intervention PCI Ranolazine Coronary Angiogram Cardioprotectant
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 6
Healthy volunteers: no

Brief summary:
The investigators will test if upfront dosing of Ranolazine can reduce myocardial biomarker release (CK-MB, Troponin) post percutaneous coronary intervention (PCI).

Detailed description:
Ranolazine has been demonstrated to decrease angina, ischemia on perfusion imaging, improve diastolic function, and cardiac metabolism. Furthermore it has been associated with reduced cardiac arrhythmias, including non-sustained ventricular tachycardia and atrial fibrillation. It has not been studied as an acute cardioprotective agent in percutaneous coronary intervention (PCI).

We hypothesize that upfront administration of Ranolazine could decrease the myocardial injury associated with PCI due to all the factors listed above (i.e. precondition the myocardium). We plan to screen all patients scheduled for an elective coronary angiogram. Those who meet criteria and consent will be randomized to either receive Ranolazine or placebo twice a day for 3 days leading up to the PCI.

Arms:
arm 1: Oral treatment Intervention: Drug: Ranolazine 1000 mg arm 2: Oral treatment Intervention: Drug: Placebo

Interventions: intervention 1: Ranolazine intervention 2: Placebo
Intervention descriptions: intervention 1: Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI intervention 2: Drug: Placebo Oral dose twice per day for 3 days leading up to PCI

Protocol document: